Skip to main content
Download PDF

Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes

Alzheimer's Research & Therapy volume 12, Article number: 40 (2020) Cite this article

Abstract

Background

Both Alzheimer’s disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage. AD has no successful treatment, and the close relationship between both diseases supports the study of antidiabetic drugs to limit or slow down brain pathology in AD. Empagliflozin (EMP) is a sodium-glucose co-transporter 2 inhibitor, the newest class of antidiabetic agents. EMP controls hyperglycemia and reduces cardiovascular comorbidities and deaths associated to T2D. Therefore, we have analyzed the role of EMP at the central level in a complex mouse model of AD-T2D.

Methods

We have treated AD-T2D mice (APP/PS1xdb/db mice) with EMP 10 mg/kg for 22 weeks. Glucose, insulin, and body weight were monthly assessed. We analyzed learning and memory in the Morris water maze and the new object discrimination test. Postmortem brain assessment was conducted to measure brain atrophy, senile plaques, and amyloid-β levels. Tau phosphorylation, hemorrhage burden, and microglia were also measured in the brain after EMP treatment.

Results

EMP treatment helped to maintain insulin levels in diabetic mice. At the central level, EMP limited cortical thinning and reduced neuronal loss in treated mice. Hemorrhage and microglia burdens were also reduced in EMP-treated mice. Senile plaque burden was lower, and these effects were accompanied by an amelioration of cognitive deficits in APP/PS1xdb/db mice.

Conclusions

Altogether, our data support a feasible role for EMP to reduce brain complications associated to AD and T2D, including classical pathological features and vascular disease, and supporting further assessment of EMP at the central level.

Background

Aging remains the main risk factor to suffer Alzheimer’s disease (AD). However, metabolic disorders, and type 2 diabetes (T2D) concretely, are also relevant contributors [1]. In this sense, diabetes has been associated with a 1.5- to 2.5-fold greater risk of dementia (for review, see [2]), and the duration of diabetes has been associated with reduced hippocampal volumes [3]. While the ultimate pathways responsible for the increased risk of dementia in T2D patients have not been elucidated, hyperglycemia, vascular alterations, impaired insulin signaling, and affected amyloid clearance have been pointed out as some of the most relevant underlying possibilities. Moreover, T2D per se is associated with cognitive dysfunction that can range from subtle diabetes-associated cognitive decrements to pre-dementia and dementia [4]. On the other hand, AD has no successful treatment, and therapeutic efforts have been directed towards classical neuropathological features that include gamma-secretase modulators, BACE1 inhibitors, immunotherapy, or tau-based therapies [5,6,7]. However, different limitations have been raised [8] reducing the presently approved treatments to acetylcholinesterase inhibitors and glutamate antagonist memantine [9]. The close relationship between T2D and AD has resulted in studies based on metabolic approaches, such as intranasal insulin administration [10] or antidiabetic agents [11, 12].

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the newest class of oral anti-hyperglycemic agents approved for the treatment of diabetes mellitus [13]. SGLT2i lower glucose levels independent of insulin, by limiting tubular glucose reabsorption. Moreover, among SGLT2i, empagliflozin (EMP) has been deeply analyzed in the EMPA-REG OUTCOME trial, and EMP limits renal disease and reduces cardiovascular and total mortality in patients [14, 15]. Following this idea, it has been suggested that EMP should be considered in patients with T2D and all forms of atherosclerotic cardiovascular disease, to reduce mortality and hospitalization for heart failure [14]. Moreover, the mechanisms responsible for the reductions in cardiovascular risk with EMP remain to be fully elucidated, and the protective cardiorenal effects of EMP seem to be largely independent of its glucose-lowering effects [15]. It has been suggested that SGLT2i, as a glucose-lowering therapy, might be associated with an increased risk of stroke [16]. However it seems that this only reaches statistical significance in specific subgroups (patients under 65 years, patients with increased glycosylated hemoglobin, and patients taking insulin treatment). Therefore, it is also argued that the hazard ratio is within the realm of chance [16]. In addition, long-term treatment with EMP to diabetic mice has shown that learning and memory are largely preserved in db/db mice, and cognitive improvement is accompanied by a reduction of oxidative stress markers in the brain, including reductions in superoxide, 8-OHdG or NADPH oxidase subunits, and gp91phox and p67phox levels. Interestingly, EMP also increased BDNF, as a key protein promoting memory and neuron survival [17]. Likewise, EMP may provide neuroprotection in the diabetic mouse brain by limiting aberrant ultrastructural remodeling of the neurovascular unit, including the neuroglia [18]. Studies with rats on a high-fat diet have also reported the positive effect of SGLT2i treatment on the brain. Cognitive abilities are improved in the Morris water maze (MWM), accompanied by reduced oxidative stress, better insulin signaling, and increased synaptic activity in the hippocampus [19]. Also, SGLT2i improve the performance of mice on a high-fat diet in the new object discrimination test, along with increased neurogenesis in the dentate gyrus and synaptophysin in the striatum oriens [20]. However, to our knowledge, no other studies have assessed the role of SGLT2i on central complications associated to AD and T2D, such as amyloid pathology, microglia activation, spontaneous bleeding, or cognitive deficits. Therefore, in this study, we treat a clinically relevant mixed murine model of AD and T2D (APP/PS1xdb/db mouse) [21, 22] with EMP from 4 to 26 weeks of age, when both AD and T2D are fully established in our mouse model, to assess the direct effect of long-term EMP treatment on brain pathology. As it could be expected, EMP significantly helped to control metabolic alterations. By the end of the treatment, brain atrophy and neuronal loss were significantly reduced in diabetic mice, as well as spontaneous bleeding and microglia burden (Iba1+), as a feasible marker of brain inflammation. On the other hand, EMP treatment also reduced senile plaque (SP) burden and amyloid-β (Aβ) levels in AD mice. Moreover, behavioral assessment revealed an overall improvement of learning and memory in treated animals, supporting a role for EMP in brain pathology and behavioral consequences associated with AD and T2D.

Methods

Animals, treatments, and metabolic assessment

APP/PS1xdb/db mice were generated in our animal facility by crossing APPswe/PS1dE9 (APP/PS1) [23] and db/db [24] mice, as described [21, 22]. Control, APP/PS1, db/db, and APP/PS1xdb/db mice were randomly divided into groups, and EMP (10 mg/kg) [25] was administered in the diet, as previously described [12], from 4 to 26 weeks of age. Due to the limited amount of animals harboring both AD and T2D, males and females were included in the study, as previously done in similar studies [10, 19, 20]. Body weight as well as glucose and insulin levels was measured before treatment and every 4 weeks until sacrifice at 26 weeks. Immediately after sacrifice, the brains were harvested and weighted. The right hemispheres were dissected and snap-frozen at − 80° until use. The left hemispheres were fixed in paraformaldehyde for 2 weeks before 30-μm sections were cut. All experimental procedures were approved by the Animal Care and Use Committee of the University of Cadiz, in accordance with the Guidelines for Care and Use of experimental animals (European Commission Directive 2010/63/UE and Spanish Royal Decree 53/2013).

Morris water maze

Spatial memory was assessed 2 weeks before the sacrifice as described [26]. The acquisition phase consisted of 4 trials/day for 4 consecutive days with the platform submerged in quadrant 2. The time limit was 60 s/trial, with a 10-min inter-trial interval. Retention phases were preformed 24 and 72 h after completing the acquisition. The platform was removed, and mice were allowed to swim for 60 s. The time required to locate the platform in the acquisition phase, percentage of time spent in quadrant 2 during the retention phase, and swimming speed were analyzed using the Smart software (Panlab, Spain).

Motor activity and new object discrimination test

Motor activity assessment and new object discrimination (NOD) commenced after completing the MWM test. Motor activity was assessed by measuring the distance traveled by the mice for 30 min in the open field box. The new object discrimination commenced the next day, and episodic memory paradigms “what,” “where,” and “when” were analyzed as previously described [22].

Cresyl violet staining

Cresyl violet staining was used to unspecifically label neurons and identify brain regions of interest. Sections located 1 mm apart (from 1.5 to − 3.5 mm from the bregma) were selected, dehydrated in 70% ethanol for 15 min, and incubated in cresyl violet as previously described [12]. Images were acquired in an optical Olympus Bx60 microscope with an Olympus DP71 camera. Cell F (Olympus, Hamburg, Germany) and ImageJ software were used to measure cortical and hippocampal sizes.

NeuN/DAPI staining

Contiguous sections to those used for cresyl violet staining were incubated with anti-NeuN (Chemicon, CA, USA) (1:200) (Invitrogen, Carlsbad, CA, USA) and Alexa Fluor 594 (Molecular Probes, OR, USA) (1:1000) antibodies, followed by DAPI 1 mg/ml (Sigma, Spain) (1:3000) counterstain. SP were stained with thioflavin S (Sigma, OR) (0.01%) in H2O/ethanol (1:1) for 10 min. The percentage of NeuN-positive cells (normalized by total cells stained with DAPI) was quantified in the cortex using ImageJ software as described [12].

Prussian blue staining

Contiguous sections to those used for NeuN/DAPI staining were incubated with Prussian blue iron staining and neutral red counterstaining, as previously described [22], to analyze spontaneous hemorrhages. The ImageJ software was used to quantify hemorrhage burden, density, and individual hemorrhage size in the cortex and hippocampus.

Microglia immunostaining

Sections were pre-treated in 70% formic acid and incubated with anti-Iba1 (Wako, Osaka, Japan) (1:1000) and anti-Aβ (4G8, Covance, Greenfield, IN, USA) (1:2000) antibodies overnight at 4 °C in 0.5% BSA, followed by incubation with Alexa Fluor 488 and Alexa Fluor 594 (Molecular Probes, OR, USA) (1:1000). Sections were photographed using a Laser Olympus U-RFL-T fluorescent microscope (Olympus, Japan) and MMIcellTools software. Microglia burden in SP-free areas as well as in the close proximity of SP (up to 50 μm) was quantified as previously described [12].

SP staining

SP burden was analyzed in the cortex and hippocampus after 4G8 immunostaining and thioflavin S staining. Sections were pre-treated in 70% formic acid and incubated with 4G8 (Covance, Greenfield, IN, USA) antibody (1:2000) followed by Alexa Fluor 594 (Molecular Probes, OR, USA) antibody (1:1000). Sections were further incubated in thioflavin S (Sigma, OR, USA) (0.01%) in H2O/ethanol 1:1, mounted, and photographed using a Laser Olympus U-RFL-T fluorescent microscope (Olympus, Japan) and MMIcellTools software. The ImageJ software was used for burden analysis.

Amyloid beta levels

Soluble and insoluble (formic fraction) Aβ40 and Aβ42 levels were measured in the cortex and hippocampus by colorimetric ELISA kits (Wako, Japan) [12]. Absorbance was measured at 450 nm in a spectrophotometer (MQX200R2, BioTek Instruments, Burlington, VT, USA).

Total tau and phospho-tau levels

Total tau and tau phosphorylation levels were measured in cortical and hippocampal samples [21]. Phospho-tau clone AT8 (1:1000) (Fisher Scientific, MA, USA) and anti-total tau (1:1000) (DAKO, Denmark) antibodies were used. After normalizing to β-actin (1:2.500.000) (Sigma, USA), optical density was semi-quantified using the ImageJ software. Phospho-tau/total tau ratios were represented as the percentage of control values.

Statistical analysis

Two-way ANOVA was used for metabolic follow-up and MWM studies. One-way ANOVA for independent samples followed by Tuckey b or Tamhane tests or Kruskal-Wallis for independent samples followed by Mann-Whitney U test with Bonferroni adjustment were used in the rest of the experiments. The SPSS v.24 software was used for all statistical analysis.

Results

EMP ameliorates metabolic alterations in db/db and APP/PS1xdb/db mice

Postprandial glucose levels were monitored every 4 weeks, from 4 to 26 weeks of age, as detected by 2-way ANOVA (groupXweek) ([F(35, 334) = 2.88, **p < 0.01], statistical power 1.000). No differences in glucose levels were present by 6 weeks of age (statistical power 0.317). Severe hyperglycemia was observed in diabetic mice (db/db and APP/PS1xdb/db mice) by 10 weeks of age. While glucose levels were still increased, EMP treatment significantly reduced hyperglycemia in db/db and APP/PS1xdb/db mice, 4 weeks after the commencement of the treatment. Glycemia control was maintained in diabetes-treated mice until the end of the study at 26 weeks of age (Fig. 1a) (statistical power 1.00). No differences were detected by 2-way ANOVA (groupXweek) ([F(35, 424) = 1.21, p = 0.189], statistical power 0.965) when insulin levels were compared. However, individual weekly assessment revealed that insulin levels were significantly increased in db/db and APP/PS1xdb/db mice along the study. EMP treatment helped to maintain elevated plasmatic insulin in an attempt to control hyperglycemia in diabetic mice, up to 26 weeks of age. These data support a feasible role for EMP to reduce pancreatic exhaustion in db/db and APP/PS1xdb/db mice (statistical power > 0.899) (Fig. 1b). When we analyzed the body weight, we detected a significant groupXweek effect ([F(35, 455) = 5.70, **p < 0.01], statistical power 1.000). Body weight was significantly higher in diabetic mice from 6 weeks of age; however, as the disease progresses, the cachectic effect of diabetes is observed. EMP treatment contributed to maintain body weight in db/db and APP/PS1xdb/db mice (statistical power > 1.00) (Fig. 1c), as previously observed with other antidiabetic treatments [21, 22].

Fig. 1
figure1

EMP treatment limits metabolic alterations in db/db and APP/PS1xdb/db mice. a Long-term EMP treatment significantly reduced postprandial glucose levels in diabetic mice. No differences were detected at week 6 ([F(7, 36)=0.864, p = 0.543], statistical power 0.317), although differences were detected from week 10 to week 22 (week 10 [F(7, 33)=18.91], week 14 [F(7, 67) = 32.92], week 18 [F(7, 69) = 31.68], week 22 [F(7, 66) = 25.12]; ‡‡p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, and APP/PS1xdb/db-EMP; ††p < 0.01 vs. control, control-EMP, APP/PS1, and APP/PS1-EMP]). b When insulin levels were analyzed, individual weekly assessment revealed that EMP treatment helped to maintain high insulin levels in db/db and APP/PS1xdb/db mice as the disease progresses (week 6 [F(7, 75) = 2.29, p = 0.036], week 10 [F(7, 74) = 4.47], week 14 [F(7, 69) = 5.23], week 18 [F(7, 68) = 5.42], week 22 [F(7, 69) = 4.49], week 26 [F(7, 69) = 6.89]; ╫╫p < 0.01 vs. control, control-EMP, and APP/PS1]; ‡‡p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, and db/db; ††p < 0.01 vs. control, control-EMP, APP/PS1, and APP/PS1-EMP; ##p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, db/db, and APP/PS1xdb/db). c Body weight was maintained by EMP, as revealed by weekly assessment (week 6 [F(7, 75) = 6.21], week 10 [F(7, 73) = 34.13], week 14 [F(7, 76) = 42.39], week 18 [F(7, 77) = 44.34], week 22 [F(7, 77) = 55.71], week 26 [F(7, 77) = 52.55]; ††p < 0.01 vs. control, control-EMP, APP/PS1, and APP/PS1-EMP]; ##p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, and db/db; ††p < 0.01 vs. control, control-EMP, APP/PS1, and APP/PS1xdb/db; **p < 0.01 vs. rest of the groups) (control n = 13, control-EMP n = 10, APP/PS1 n = 9, APP/PS1-EMP n = 11, db/db n = 11, db/db-EMP n = 10–12, APP/PS1xdb/db n = 9, APP/PS1xdb/db-EMP n = 10)

Full size image

EMP improves learning and memory in AD, T2D, and AD-T2D mice

We used a very demanding version of the NOD task, and we observed that episodic memory was slightly affected in APP/PS1 and db/db mice at 26 weeks of age, and the impairment was more severe in APP/PS1xdb/db mice. EMP treatment significantly improved the performance in the NOD test for all paradigms under study (“what,” “where,” and “when,” statistical power > 0.921) (Fig. 2a).

Fig. 2
figure2

Cognitive impairment in APP/PS1xdb/db mice was ameliorated by EMP treatment. a EMP treatment significantly improved the performance in the NOD test for all paradigms under study (“what” [F(7, 207) = 2.88], “where” [F(7, 208) = 3.17], “when” [F(7, 214) = 3.79]; ##p < 0.01 vs. control, control-EMP, and APP/PS1-EMP; ††p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, db/db, and db/db-EMP; ‡‡p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, db/db-EMP, and APP/PS1xdb/db-EMP). b In the MWM, EMP treatment reduced acquisition times in APP/PS1, db/db, and APP/PS1xdb/db mice (day 1 [F(7, 298)=3.85], day 2 [F(7, 288) = 14.33], day 3 [F(7, 280) = 13.27], day 4 [F(7, 284) = 18.24]; **p < 0.001 vs. the rest of the groups; ††p < 0.001 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, and db/db-EMP; ╫╫p < 0.01 vs. control, control-EMP, and APP/PS1-EMP; ₸₸p < 0.01 vs. control and control-EMP). c EMP ameliorated the impairment observed along retention 1 (24 h);, however no statistical differences were detected among the groups [F(7, 69) = 1.65, p = 0.134]. On retention 2 (72 h), reduced cognitive abilities in db/db and APP/PS1xdb/db mice were reversed by EMP treatment [F(7, 68) = 4.40, ‡‡p < 0.001 vs. control and control-EMP] (control n = 11, control-EMP n = 13, APP/PS1 n = 10, APP/PS1-EMP n = 10, db/db n = 9, db/db-EMP n = 10, APP/PS1xdb/db n = 5, APP/PS1xdb/db-EMP n = 9)

Full size image

Acquisition in the MWM revealed that APP/PS1 and db/db mice were cognitively impaired, and a synergistic effect was observed in APP/PS1xdb/db mice. EMP treatment reduced acquisition times in APP/PS1, db/db, and APP/PS1xdb/db mice. We detected a significant dayXgroup effect by 2-way ANOVA for independent samples ([F(21, 1150) = 1.87, *p = 0.01], statistical power 0.986), and individual day assessment confirmed the improvement as trials were conducted (statistical power > 0.980) (Fig. 2b). Along retention 1 (24 h after completing the acquisition phase), the time spent in quadrant 2 (where the platform used to be located) was reduced for APP/PS1, db/db, and APP/PS1xdb/db mice, whereas EMP treatment ameliorated this situation; however, no statistical differences were detected among the groups (statistical power = 0.640) (Fig. 2c). On retention 2 (72 h after completing the acquisition phase), memory was compromised in APP/PS1, db/db, and APP/PS1xdb/db mice, when compared with wild-type animals. Altered cognitive abilities in db/db and APP/PS1xdb/db mice were reversed by EMP treatment (statistical power = 0.987) (Fig. 2c).

When we measured the total distance traveled, to analyzed motor activity, no significant differences were observed (control, 12052.90 ± 1329.56; control-EMP, 12003.58 ± 681.15; APP/PS1, 11289.92 ± 1012.64; APP/PS1-EMP, 10351.01 ± 974.93; db/db, 11859.18 ± 2197.19; db/db-EMP, 9968.56 ± 763.54; APP/PS1xdb/db, 13422.28 ± 2203.02; and APP/PS1xdb/db-EMP, 8268.43 ± 525.504; [F(7, 69) = 1.57, p = 0.157], statistical power 0.614), supporting that observed differences in cognitive tests were not derived from altered motor activity.

Brain atrophy is reduced in diabetic mice after EMP treatment

Brain atrophy in db/db and APP/PS1xdb/db mice was improved after EMP treatment, when the hemisection and cortical areas were measured (statistical power > 0.970) (Fig. 3a, c). While a similar profile was observed in the hippocampus, differences did not reach statistical significance (statistical power 0.276) (Fig. 3a). Similarly, cortical thickness was significantly reduced in diabetic mice, and EMP helped to reverse this situation (statistical power 0.884) (Fig. 3b, c). To further characterize the observed atrophy, we also analyzed the neuronal density in the cortex. NeuN/DAPI ratio was reduced in the cortex from APP/PS1, db/db, and APP/PS1xdb/db mice, both in the proximity of SP and far from plaques, while EMP treatment significantly reversed this situation (statistical power > 0.959) (Fig. 3d, e).

Fig. 3
figure3

Brain atrophy was ameliorated by EMP treatment. a Brain atrophy in db/db and APP/PS1xdb/db mice was improved after EMP treatment, when the hemisection size and cortical areas were analyzed (hemisection [F(7, 205) = 6.23]; hemicortex [F(7, 191) = 3.59]; ††p < 0.01 vs. control, control-EMP, APP/PS1, and APP/PS1-EMP]; ┬p < 0.01 vs. control). While a similar profile was observed in the hippocampus, differences did not reach statistical significance [F(7, 107) = 0.718; p = 0.657] (control n = 7, control-EMP n = 9, APP/PS1 n = 6, APP/PS1-EMP n = 5, db/db n = 6, db/db-EMP n = 7, APP/PS1xdb/db n = 6, APP/PS1xdb/db-EMP n = 5). b Cortical thickness was also improved after EMP treatment [F(7, 419)=2.53; ♯♯p < 0.01 vs. APP/PS, db/db-EMP, and APP/PS1xdb/db-EMP]. c Illustrative example of cresyl violet staining where cortical thinning observed in db/db and APP/PS1xdb/db mice is restored by EMP treatment. Scale bar = 125 μm. d NeuN/DAPI ratios were reduced in the proximity and far from SP, and EMP treatment reversed this situation (close to plaques [F(3, 933) = 6.017, ††p < 0.001 vs. APP/PS1-EMP and APP/PS1xdb/db-EMP; ‡‡p < 0.01 vs. APP/PS1xdb/db-EMP]; far from plaques [F(7, 3029) = 15.86, ₸₸p < 0.001 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, db/db-EMP, and APP/PS1xdb/db-EMP; ##p < 0.01 vs. control-EMP and APP/PS1-EMP]) (control n = 5, control-EMP n = 4, APP/PS1 n = 5, APP/PS1-EMP n = 4, db/db n = 5, db/db-EMP n = 4, APP/PS1xdb/db n = 5, APP/PS1xdb/db-EMP n = 4). e Illustrative example of NeuN/DAPI staining in the proximity and far from SP in the cortex. Scale bars = 25 μm

Full size image

Spontaneous bleeding is reduced by EMP treatment

As previously described, the burden of spontaneous hemorrhages was higher in db/db and APP/PS1xdb/db mice [21, 22], whereas EMP treatment counterbalanced this situation (statistical power = 0.997) (Fig. 4a, b). This effect was due to a reduction in hemorrhage density, while individual hemorrhage size was not affected (data not shown). We observed a similar profile in the hippocampus, although differences did not reach statistical significance (statistical power = 0.723) (Fig. 4a).

Fig. 4
figure4

Spontaneous bleeding and inflammation were reduced after EMP treatment. a EMP reduced hemorrhage burden in the cortex, and while a similar profile was observed in the hippocampus, differences were not statistically significant (cortex [F(7, 262) = 2.65, †p = 0.011 vs. control, control-EMP, APP/PS1, and APP/PS1-EMP]; hippocampus [F(7, 118) = 01.85, p = 0.081]) (control n = 8, control-EMP n = 6, APP/PS1 n = 5, APP/PS1-EMP n = 4, db/db n = 7, db/db-EMP n = 6, APP/PS1xdb/db n = 4, APP/PS1xdb/db-EMP n = 6). b Illustrative example of Prussian blue staining in all groups under study. Green arrows point at individual hemorrhages. Scale bar = 100 μm. c Cortical microglia burden was lower in the proximity of SP in APP/PS1xdb/db mice ([F(3, 534) = 7.036], ‡‡p < 0.01 vs. APP/PS1 and APP/PS1-EMP, ┬┬p < 0.01 vs. APP/PS1]), while in SP-free areas, increased burden was reduced after EMP treatment ([F(7, 4465)=137.36, **p < 0.01 vs. the rest of the groups, ₸₸p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, db/db-EMP, and APP/PS1xdb/db-EMP; ††p < 0.01 vs. control, control-EMP, APP/PS1-EMP, and APP/PS1xdb/db-EMP, ##p < 0.01 vs. APP/PS1-EMP and APP/PS1xdb/db-EMP]). A similar profile was observed in the hippocampus, and microglia burden was reduced after EMP treatment in SP-free areas (close to plaques ([F(3, 39)=2.21, p = 0.91]); far from plaques [F(7, 768) = 23.79, ╫╫p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, and APP/PS1xdb/db-EMP, ††p < 0.01 vs. control, control-EMP, APP/PS1-EMP, and APP/PS1xdb/db-EMP, ♯♯p < 0.01 vs. control and control-EMP]) (control n = 5, control-EMP n = 5, APP/PS1 n = 5, APP/PS1-EMP n = 4, db/db n = 6, db/db-EMP n = 4, APP/PS1xdb/db n = 4, APP/PS1xdb/db-EMP n = 5). d Illustrative example of the cortical areas immunostained for Iba-1 (green) and SP (4G8, red). Circles point out representative regions close and far from SP. Scale bar = 125 μm

Full size image

Iba1+ burden is reduced after EMP treatment

Cortical microglia burden was significantly lower in APP/PS1xdb/db mice in the close proximity to SP (statistical power 0.997) in line with previous observations [21, 22]. In SP-free areas, microglia burden was increased in db/db and APP/PS1xdb/db mice and EMP treatment reduced microglia burden (statistical power 1.00) (Fig. 4c, d). While a similar profile was observed in the hippocampus, microglia burden was not significantly affected in areas close to plaques (statistical power = 0.546). In SP-free areas, increased microglia burden in db/db and APP/PS1xdb/db mice was slightly reduced after EMP treatment (statistical power 1.000) (Fig. 4c).

EMP treatment reduced amyloid pathology in APP/PS1 and APP/PS1xdb/db mice

SP burden was significantly lower in the cortex from APP/PS1xdb/db mice, as previously described in this animal model [21, 22]. EMP treatment slightly reduced SP burden in APP/PS1 and APP/PS1xdb/db mice (statistical power 1.000) (Fig. 5a), although SP were slightly larger in APP/PS1-EMP mice (statistical power > 0.996) (Fig. 5a). However, SP density was reduced by EMP treatment in APP/PS1 animals (statistical power 1.000) (Fig. 5a, b). To a lesser extent, we observed a similar trend when we analyzed SP burden (statistical power > 0.946), density (statistical power > 0.995), and individual plaque size in the hippocampus (statistical power > 0.267) (Fig. 5c).

Fig. 5
figure5

Amyloid pathology is reduced by EMP treatment. a SP burden was lower in APP/PS1xdb/db mice when compared with APP/PS1 animals. EMP treatment slightly reduced SP burden in the cortex after TS and 4G8 staining (TS [F(3, 107) = 20.55], 4G8 [F(3, 104) = 11.89]; ††p < 0.01 vs. APP/PS1 and APP/PS1-EMP). While individual SP size was increased in APP/PS-EMP mice (TS [F(3, 5191) = 8.98], 4G8 [F(3, 5039) = 21.11]; ‡‡p < 0.01 vs. APP/PS1-EMP; ††p < 0.01 vs. APP/PS1 and APP/PS1-EMP), EMP treatment reduced SP density (TS [F(3, 107) = 19.74], 4G8 [F(3, 107) = 17.81]; ‡‡p < 0.01 vs. APP/PS1; ††p < 0.01 vs. APP/PS1 and APP/PS1-EMP). To a lesser extent, we observed a similar trend when we analyzed SP burden in the hippocampus (TS [F(3, 49) = 8.01], 4G8 [F(3, 49) = 6.08]; ‡‡p < 0.01 vs. APP/PS1]), SP density (TS [F(3, 50) = 11.57], 4G8 [F(3, 50) = 9.42]; ‡‡p < 0.01 vs. APP/PS1), and individual plaque size (TS [F(3, 643) = 0.975, p = 0.404]; 4G8 [F(3, 638) = 2.39, p = 0.067]) (APP/PS1 n = 5, APP/PS1-EMP n = 5, APP/PS1xdb/db n = 5, APP/PS1xdb/db-EMP n = 5). b Illustrative example of cortical regions stained with TS and 4G8 where reduced SP density can be observed after EMP treatment. Scale bar = 50 μm. c A similar profile was observed in the hippocampus when we measured SP burden, density, and individual SP size (‡‡p < 0.01 vs. APP/PS1) (APP/PS1 n = 5, APP/PS1-EMP n = 5, APP/PS1xdb/db n = 5, APP/PS1xdb/db-EMP n = 5). d EMP treatment reduced soluble Aβ40 levels in the cortex ([F(3, 27) = 4.20, ‡p = 0.015 vs. APP/PS1xdb/db]). While a similar trend was observed in the hippocampus, differences were not statistically significant ([F(3, 26)=0.479, p = 0.7]). No differences were observed for soluble Aβ42 levels in the cortex ([F(3, 27) = 0.832, p = 0.488]) or the hippocampus ([F(3, 26) = 1.02, p = 0.397]). EMP also reduced insoluble Aβ40 levels in the cortex ([F(3, 25) = 5.98, **p = 0.003 vs. the rest of the groups]), while differences did not reach statistical significance for insoluble Aβ40 in the hippocampus ([F(3, 22) = 2.68, p = 0.072]) as well as for insoluble Aβ42 levels (cortex [F(3, 27) = 1.43, p = 0.254]; hippocampus [F(3, 26) = 1.54, p = 0.228]) (APP/PS1 n = 7, APP/PS1-EMP n = 9, APP/PS1xdb/db n = 7, APP/PS1xdb/db-EMP n = 7)

Full size image

We also assessed amyloid levels in the cortex and the hippocampus. In line with previous observations, we detected a shift in the natural history of Aβ deposition, and soluble, more toxic species were favored in APP/PS1xdb/db mice, while insoluble Aβ levels were lower, in line with our observations in SP quantification. EMP treatment reduced soluble Aβ40 levels in the cortex (statistical power 0.800) (Fig. 5d). The same profile was observed for Aβ40 levels in the hippocampus (statistical power 0.133), as well as for soluble Aβ42 levels (both in the cortex and hippocampus); however, differences did not reach statistical significance (statistical power > 0.206) (Fig. 5d). EMP also reduced insoluble Aβ40 levels in the cortex (statistical power 0.923) (Fig. 5d), whereas no differences were observed when insoluble Aβ42 levels were compared (statistical power 0.336). Insoluble Aβ40 (statistical power 0.572) and Aβ42 (statistical power 0.357) levels were not significantly affected in the hippocampus (Fig. 5d).

EMP treatment limits tau phosphorylation

Tau phosphorylation was increased in APP/PS1, and more robustly in db/db and APP/PS1xdb/db mice, as previously described. EMP treatment ameliorated this situation in the cortex from db/db-treated mice (χ2 = 32.11, p = 0.008, ##p < 0.01 vs. control, statistical power 0.934) (supplementary figure 1a and b). A similar profile was observed in the hippocampus, although differences did not reach statistical significance (χ2 = 3.74, p = 0.809, statistical power 0.337) (supplementary figure 1a and b).

Discussion

AD has no successful treatment, and patients are in a tremendous need of new therapeutic approaches. The close relationship between T2D and AD has been previously suggested as a relevant target to slow down or reduce brain complications [12, 27, 28]. Following this idea, SGLT2i are the newest oral antidiabetic drugs, and previous studies have focused on characterizing metabolic and peripheral action of these agents. Among SGLT2i, EMP has been shown to control metabolic-related alterations and reduce mortality in patients [29]. However, the role of SGLT2i on the central nervous system has been scarcely addressed in diabetes models [17,18,19], and to our knowledge, no specific studies have analyzed SGLT2i on AD central pathology.

As expected, EMP ameliorated metabolic alterations, and glucose levels were reduced in diabetic mice. SGLTi mechanism of action is insulin independent; however, since db/db mice are a leptin receptor functional KO model, they are severely diabetic and glucose levels cannot be normalized by EMP treatment. However, we detected that diabetic hyperinsulinemia was longer maintained after EMP treatment, in a similar trend to that previously described in SGLTi-treated db/db mice [30]. These observations are consistent with the maintenance of β-pancreatic activity and insulin levels in diabetic mice after the SGLTi administration [31]. While body weight control has been observed in patients treated with SGLT2i [32, 33], in our hands, long-term EMP treatment maintained body weight, as previously described in db/db cachectic mice treated with SGLTi [30].

Postmortem assessment of EMP-treated mice revealed that brain atrophy observed in diabetic animals was significantly ameliorated. Our previous characterization of db/db [26] and APP/PS1xdb/db mice [21, 22] revealed a preferential affectation of the cortex in these animal models with a slight compromise of the hippocampus. Whereas neuronal loss is not observed in APP/PS1 animals [34], when APP/PS1 mice are crossed with db/db mice, brain atrophy is observed as the disease progresses in APP/PS1xd/db mice, making the model more complex, and better resembling actual AD pathology. In our hands, EMP treatment also helped to keep NeuN/DAPI ratios, suggesting a role for EMP in maintaining the neuroregenerative capacity both in the proximity and far from senile plaques. On the whole, EMP treatment successfully limits cortical thinning and maintains neuronal density after long-term administration, as previously described with other antidiabetic treatments [12, 35, 36].

Vascular disease has been closely associated to AD and T2D, and a synergistic effect has been reported when both pathologies coexist. Spontaneous bleeding is a neuropathological feature that affects db/db mice and more severely APP/PS1xdb/db animals, reproducing brain small vessel disease. In our hands, vascular disease parameters did not correlate with NeuN/DAPI ratios (data not shown), and it is feasible that a combination of all alterations (vascular damage, microglia activation, amyloid pathology, and metabolic alteration) is synergistically responsible for observed cognitive impairment. However, Bello-Chavolla et al. [37] have recently reviewed neuroimaging and neuropathology studies supporting a role for neurodegeneration and cerebrovascular lesions, specifically small vessel disease, in the onset of dementia, consistent with the increased risk of dementia in T2D patients. EMP treatment significantly ameliorated the microhemorrhage burden in the cortex, the most severely affected brain region. These observations are in agreement with previous ultrastructural studies, showing that EMP treatment reduces attenuation and/or loss of pericytes as well as endothelial cell tight and adherents junctions and prevents endothelial dysfunction in different diabetic models [18, 38].

Inflammation is a major component, both in T2D and AD [39], that may underlie the close relationship between T2D and AD [40]. Likewise, hypoglycemic agents show anti-inflammatory activity [41]. Moreover, these anti-inflammatory effects are also detected at the central level with metformin [42], liraglutide [43], multitarget agents [28], or combined therapies [12]. In our hands, EMP also reduced microglia burden in the parenchyma from db/db and APP/PS1xdb/db mice. Our studies are limited to microglia assessment, by Iba1 immunostaining, and therefore, the whole complexity of the inflammatory process is not covered. However, our observations are in accordance with other studies showing that EMP may reduce oxidative stress, astrocyte activation, and inflammation in diabetic models [18, 38]. While the underlying mechanisms have not been completely elucidated, SGLT2i anti-inflammatory activity might be related to increased levels of anti-inflammatory ketone bodies, decreased interface of immune cells with glucose, or reduced insulin and uric acid levels, among others [44].

Amyloid pathology is altered in our AD-T2D model, and more toxic soluble Aβ species are favored in the mixed model; nevertheless, insoluble Aβ is reduced [21, 22]. These observations support a shift in the natural history of Aβ deposition, and whereas soluble Aβ species tend to be increased, insoluble Aβ and SP are reduced. These data are in line with those by Niedowicz et al. [45] reporting an increase of oligomeric Aβ without an effect on Aβ deposition, when AD and T2D are set together, in a similar mouse model. Other studies have reported limited changes in total Aβ levels and increased amyloid angiopathy in young APP23xob/ob mice [46]. Likewise, studies with APP/PS1 mice on a high-fat diet or APP/PS1 mice crossbred with pancreatic insulin-like growth factor 2 overexpressing mice have failed to increase Aβ burden in the brain [47]. We observed that EMP treatment reduces SP density, and an overall reduction of soluble and insoluble Aβ levels is detected in the cortex and the hippocampus from EMP-treated mice. Whereas we cannot point towards a specific mechanism, other antidiabetic treatments have also shown to reduce amyloid pathology [21, 48, 49], based not only on metabolic control but also on their effects on oxidative stress, inflammation, or the blood-brain barrier.

Tau phosphorylation is also increased in diabetic mice, and although EMP reverted this situation in db/db mice, the overall effect was limited. Nevertheless, it also needs to be taken into consideration that APP/PS1 mice do not present overt tau pathology, limiting the outcomes at this level. It seems well established that insulin resistance may increase tau pathology by interfering the balance between tau kinases and phosphatases Tau also modulates insulin signaling [50], contributing to the cross-talk between both pathologies. We have previously observed similar outcomes with other antidiabetic treatments [12]. In line with these observations, pioglitazone has also been shown to reduce tau oligomerization, phospho, and total tau levels, and it also inactivates glycogen synthase kinase 3β in primary neuronal cultures [51].

As previously shown, AD-T2D mice present severe learning and memory compromises [21, 22]. Leptin signaling dysfunction has been associated to central complications, including cognitive impairment [52] or long-term potentiation [53], and therefore, we cannot exclude our findings that it might be at least partially due to altered leptin signaling. However, we observed a better performance of EMP-treated mice in the MWM. Other studies have shown the positive effect of antidiabetic agents in learning and memory [54], and SGLT2i have also been shown to improve cognitive impairment in other metabolic disease models [17, 19].

While to our knowledge, there are no previous studies analyzing the effect of SGLT2i on AD animal models, the beneficial effect of SGLT2i canagliflozin in rats with scopolamine-induced memory impairment has been reported. In this animal model, improvement in the MWM is attributed to the inhibition of acetylcholinesterase activity and monoamine levels in the brain. Canagliflozin might act as a dual acetylcholinesterase and SGLT2i [55], supporting a dual role for SGLT2i at the central level [56, 57] and opening an interesting venue, since acetylcholinesterase inhibitors, and NMDA receptor antagonist memantine, are the only FDA-approved options to treat AD. In our learning and memory studies, we additionally used a very demanding version of the NOD task, which allows the assessment of episodic memory [58]. We also observed an overall improvement after EMP treatment, in line with previous studies [59]. Cognitive enhancement cannot be attributed to a single effect, however it is feasible that by reducing microglia burden, vascular damage, and amyloid pathology, EMP consequently improves learning and memory in AD-T2D mice. Also, the large number of groups in the study also limits the detection of post hoc differences, making it hard to disentangle the direct effect of EMP on AD mice. However, when we analyzed AD mice (APP/PS1 and APP/PS1-EMP) separately, we observed an overall improvement of different pathological features, including cortical NeuN/DAPI ratio, microglia burden in the proximity of SP, or SP density in the cortex and hippocampus, accompanied by better performance in the MWM test, supporting a role for EMP specifically associated to AD pathology in APP/PS1 mice. It also needs to be pointed out that whereas APP/PS1 mice show limited behavioral complications by 6 months of age, db/db mice present severe pathology that limits the chances to take APP/PS1xdb/db mice to older ages. This situation also precludes the possibility to obtain relevant information after the long-term evolution of both pathologies, as commonly observed in the clinic. Nevertheless, APP/PS1xdb/db mice are a relevant model that offers the possibility of assessing both AD and T2D pathological features, offering a more complex version of the process.

Conclusion

Altogether, our results suggest a role for EMP to reduce brain complications associated to T2D and AD, including classical AD features and vascular disease. Whereas these are initial studies on animal models, the close relationship between AD and T2D may support further assessment of T2D patients treated with EMP, in order to provide new insights into the effects of EMP on the brain.

Availability of data and materials:

Data are available upon reasonable request.

Abbreviations

AD:

Alzheimer’s disease

Aβ:

Amyloid-β

EMP:

Empagliflozin

MWM:

Morris water maze

NOD:

New object discrimination

SP:

Senile plaque

SGLT2i:

Sodium-glucose co-transporter 2 inhibitors

T2D:

Type 2 diabetes

References

  1. 1.

    Salas IH, De Strooper B. Diabetes and Alzheimer’s disease: a link not as simple as it seems. Neurochem Res. 2018;44(6):1271–8.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Ninomiya T. Epidemiological evidence of the relationship between diabetes and dementia. Adv Exp Med Biol. 2019;1128:13–25.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Hirabayashi N, Hata J, Ohara T, Mukai N, Nagata M, Shibata M, et al. Association between diabetes and hippocampal atrophy in elderly Japanese: the Hisayama Study. Diabetes Care. 2016;39(9):1543–9.

    PubMed  Article  Google Scholar 

  4. 4.

    Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604.

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Braczynski AK, Schulz JB, Bach JP. Vaccination strategies in tauopathies and synucleinopathies. J Neurochem. 2017;143(5):467–88.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Das B, Yan R. A close look at BACE1 inhibitors for Alzheimer’s disease treatment. CNS Drugs. 2019;33(3):251–63.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Xia W. Gamma-secretase and its modulators: twenty years and beyond. Neurosci Lett. 2019;701:162–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, et al. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology. 2018;90(10):e877–e86.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine. Ther Adv Drug Saf. 2018;9(3):171–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Santiago JCP, Hallschmid M. Outcomes and clinical implications of intranasal insulin administration to the central nervous system. Exp Neurol. 2019;317:180–90.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Holscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models. Neuropharmacology. 2018;136(Pt B):251–9.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Infante-Garcia C, Ramos-Rodriguez JJ, Hierro-Bujalance C, Ortegon E, Pickett E, Jackson R, et al. Antidiabetic polypill improves central pathology and cognitive impairment in a mixed model of Alzheimer’s disease and type 2 diabetes. Mol Neurobiol. 2018;55(7):6130–44.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–80.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  14. 14.

    Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384–95.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138(17):1904–7.

    PubMed  Article  Google Scholar 

  16. 16.

    Bonnet F, Scheen AJ. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. Diabetes Metab. 2017;43(4):299–313.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  18. 18.

    Hayden MR, Grant DG, Aroor AR, DeMarco VG. Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse. Brain Sci. 2019;9(3):57. Published 2019 Mar 7. doi: https://doi.org/10.3390/brainsci9030057.

  19. 19.

    Sa-Nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43–50.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Millar P, Pathak N, Parthsarathy V, Bjourson AJ, O’Kane M, Pathak V, et al. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. J Endocrinol. 2017;234(3):255–67.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Infante-Garcia C, Ramos-Rodriguez JJ, Galindo-Gonzalez L, Garcia-Alloza M. Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimer’s disease and type 2 diabetes. Psychoneuroendocrinology. 2016;65:15–25.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Ramos-Rodriguez JJ, Jimenez-Palomares M, Murillo-Carretero MI, Infante-Garcia C, Berrocoso E, Hernandez-Pacho F, et al. Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer’s disease. Psychoneuroendocrinology. 2015;62:69–79.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13(2):159–70.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science. 1966;153(3740):1127–8.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016;65(2):114–23.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Ramos-Rodriguez JJ, Ortiz O, Jimenez-Palomares M, Kay KR, Berrocoso E, Murillo-Carretero MI, et al. Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology. 2013;38(11):2462–75.

    PubMed  Article  Google Scholar 

  27. 27.

    Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST. Neuroprotective actions of glucagon-like peptide-1 (GLP-1) analogues in Alzheimer’s and Parkinson’s diseases. CNS Drugs. 2019;33(3):209–23.

    PubMed  Article  Google Scholar 

  28. 28.

    Tai J, Liu W, Li Y, Li L, Holscher C. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease. Brain Res. 1678;2018:64–74.

    Google Scholar 

  29. 29.

    Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol. 2018;71(3):364–7.

    PubMed  Article  Google Scholar 

  30. 30.

    Sugizaki T, Zhu S, Guo G, Matsumoto A, Zhao J, Endo M, et al. Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality. NPJ Aging Mech Dis. 2017;3:12.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  31. 31.

    Al Jobori H, Daniele G, Adams J, Cersosimo E, Solis-Herrera C, Triplitt C, et al. Empagliflozin treatment is associated with improved beta-cell function in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2018;103(4):1402–7.

    PubMed  Article  Google Scholar 

  32. 32.

    Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity (Silver Spring). 2018;26(1):70–80.

    CAS  Article  Google Scholar 

  33. 33.

    Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119–26.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Perez SE, Dar S, Ikonomovic MD, DeKosky ST, Mufson EJ. Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. Neurobiol Dis. 2007;28(1):3–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    He W, Tian X, Lv M, Wang H. Liraglutide protects neurite outgrowth of cortical neurons under oxidative stress though activating the Wnt pathway. J Stroke Cerebrovasc Dis. 2018;27(10):2696–702.

    PubMed  Article  Google Scholar 

  36. 36.

    He W, Wang H, Zhao C, Tian X, Li L. Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke. J Cell Physiol. 2020;235(3):2986–3001.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vazquez A, Avila-Funes JA, Aguilar-Salinas CA. Pathophysiological mechanisms linking type 2 diabetes and dementia: review of evidence from clinical, translational and epidemiological research. Curr Diabetes Rev. 2019; 15(6):456-570.

  38. 38.

    Steven S, Oelze M, Hanf A, Kroller-Schon S, Kashani F, Roohani S, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014;63(7):2262–72.

    PubMed  Article  Google Scholar 

  41. 41.

    Kothari V, Galdo JA, Mathews ST. Hypoglycemic agents and potential anti-inflammatory activity. J Inflamm Res. 2016;9:27–38.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Oliveira WH, Nunes AK, Franca ME, Santos LA, Los DB, Rocha SW, et al. Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice. Brain Res. 1644;2016:149–60.

    Google Scholar 

  43. 43.

    Hou J, Manaenko A, Hakon J, Hansen-Schwartz J, Tang J, Zhang JH. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2012;32(12):2201–10.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Prattichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20(11):2515–22.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Niedowicz DM, Reeves VL, Platt TL, Kohler K, Beckett TL, Powell DK, et al. Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol Commun. 2014;2:64.

    PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010;107(15):7036–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Hiltunen M, Khandelwal VK, Yaluri N, Tiilikainen T, Tusa M, Koivisto H, et al. Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J Cell Mol Med. 2012;16(6):1206–22.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Holubova M, Hruba L, Popelova A, Bencze M, Prazienkova V, Gengler S, et al. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of beta-amyloid pathology. Neuropharmacology. 2019;144:377–87.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Holscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease. Alzheimers Dement. 2014;10(1 Suppl):S47–54.

    PubMed  Article  Google Scholar 

  50. 50.

    Gratuze M, Joly-Amado A, Vieau D, Buee L, Blum D. Mutual relationship between tau and central insulin signalling: consequences for AD and tauopathies? Neuroendocrinology. 2018;107(2):181–95.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Hamano T, Shirafuji N, Makino C, Yen SH, Kanaan NM, Ueno A, et al. Pioglitazone prevents tau oligomerization. Biochem Biophys Res Commun. 2016;478(3):1035–42.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Yook JS, Rakwal R, Shibato J, Takahashi K, Koizumi H, Shima T, et al. Leptin in hippocampus mediates benefits of mild exercise by an antioxidant on neurogenesis and memory. Proc Natl Acad Sci U S A. 2019;116(22):10988–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Wosiski-Kuhn M, Erion JR, Gomez-Sanchez EP, Gomez-Sanchez CE, Stranahan AM. Glucocorticoid receptor activation impairs hippocampal plasticity by suppressing BDNF expression in obese mice. Psychoneuroendocrinology. 2014;42:165–77.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Xourgia E, Papazafiropoulou A, Melidonis A. Antidiabetic treatment on memory and spatial learning: from the pancreas to the neuron. World J Diabetes. 2019;10(3):169–80.

    PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Arafa NMS, Ali EHA, Hassan MK. Canagliflozin prevents scopolamine-induced memory impairment in rats: comparison with galantamine hydrobromide action. Chem Biol Interact. 2017;277:195–203.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Shaikh S, Rizvi SM, Shakil S, Riyaz S, Biswas D, Jahan R. Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol Appl Biochem. 2016;63(1):145–50.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Shakil S. Molecular interaction of anti-diabetic drugs with acetylcholinesterase and sodium glucose co-transporter 2. J Cell Biochem. 2017;118(11):3855–65.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Dere E, Huston JP, De Souza Silva MA. Episodic-like memory in mice: simultaneous assessment of object, place and temporal order memory. Brain Res Brain Res Protoc. 2005;16(1–3):10–9.

    PubMed  Article  Google Scholar 

  59. 59.

    van der Kooij MA, Jene T, Treccani G, Miederer I, Hasch A, Voelxen N, et al. Chronic social stress-induced hyperglycemia in mice couples individual stress susceptibility to impaired spatial memory. Proc Natl Acad Sci U S A. 2018;115(43):E10187–E96.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the University of Cadiz Animal Facility, Ms. Consuelo Rivera, and Mr. Miguel Angel Rodriguez for their help and technical support.

Funding

CHB: Predoctoral fellowship, University of Cadiz. MG-A: Programa Estatal de I+D+I orientada a los Retos de la Sociedad (BFU 2016-75038-R), financed by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER), Ministerio de Ciencia, Innovación y Universidades, Explora Ciencia, Ministerio de Ciencia, Innovación y Universidades (BFU2017-91910-EXP). Subvención para la financiación de la investigación y la innovación biomédica y en ciencias de la salud en el marco de la iniciativa territorial integrada 2014-2020 para la provincia de Cádiz, Consejeria de Salud y Familias, Junta de Andalucia and financed by the Fondo de Desarrollo Regional (FEDER) (PI-0008-2017), Union Europea. RECOGNISED is funded by the European Commission within the Programme of Horizon 2020, grant agreement number 847749.

Author information

Affiliations

  1. Division of Physiology, School of Medicine, Universidad de Cadiz, Plaza Fragela sn, 4 piso 410, Cadiz, Spain

    Carmen Hierro-Bujalance, Carmen Infante-Garcia, Angel del Marco, Marta Herrera, Maria Jose Carranza-Naval, Javier Suarez, Pilar Alves-Martinez, Simon Lubian-Lopez & Monica Garcia-Alloza

  2. Instituto de Investigacion e Innovación en Ciencias Biomedicas de la Provincia de Cadiz (INIBICA), Cadiz, Spain

    Carmen Hierro-Bujalance, Carmen Infante-Garcia, Angel del Marco, Maria Jose Carranza-Naval, Pilar Alves-Martinez, Simon Lubian-Lopez & Monica Garcia-Alloza

  3. Salus Infirmorum-Universidad de Cadiz, Cadiz, Spain

    Maria Jose Carranza-Naval

  4. Division of Paediatrics, Section of Neonatology, Hospital Universitario Puerta del Mar, Cadiz, Spain

    Pilar Alves-Martinez & Simon Lubian-Lopez

Authors
  1. Carmen Hierro-Bujalance
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmen Infante-Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angel del Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marta Herrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Jose Carranza-Naval
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Javier Suarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pilar Alves-Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Simon Lubian-Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Monica Garcia-Alloza
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CH and CIG: experiment design, data acquisition, analysis, and interpretation. ADM, MH, MJCN, JS, and PAM: data acquisition and analysis. SLL: study concept and design, and critical revision of the manuscript for intellectual content. MGA: study concept and design, drafting, and critical revision of the manuscript for intellectual content. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Monica Garcia-Alloza.

Ethics declarations

Ethics approval and consent to participate:

All experimental procedures were approved by the Animal Care and Use Committee of the University of Cadiz, in accordance with the Guidelines for Care and Use of Experimental Animals (European Commission Directive 2010/63/UE and Spanish Royal Decree 53/2013).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1:

Figure 5. Tau pathology is reduced in db/db mice after EMP treatment.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hierro-Bujalance, C., Infante-Garcia, C., del Marco, A. et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. Alz Res Therapy 12, 40 (2020). https://doi.org/10.1186/s13195-020-00607-4

Download citation

Keywords

  • Alzheimer’s disease
  • Type 2 diabetes
  • Amyloid-β
  • Hemorrhage
  • Microglia
  • Tau
  • Cognition
  • Empagliflozin

Alzheimer's Research & Therapy

ISSN: 1758-9193

\